Navigation Links
Prescient Medical, Inc. Achieves Successful Clinical Debut of vProtect(TM) Luminal Shield
Date:5/29/2008

Novel self-expanding intracoronary prosthesis successfully placed in three

patients with coronary artery disease

DOYLESTOWN, Pa., May 29 /PRNewswire/ -- Three patients with established cardiac ischemia recently became the first recipients of the vProtect Luminal Shield, a self-expanding intracoronary prosthesis designed to limit arterial injury that typically occurs when stents are deployed. The Shield also provides robust biocompatible support for the vessel to ensure that the target coronary artery will remain patent after placement.

The patients were treated May 8-9 by Juan F. Granada, MD (Cardiovascular Research Foundation, New York, NY) and Juan A. Delgado, MD (Corbic Institute-MUA) at the Corbic Institute-MUA in Envigado, Colombia. The target lesions ranged from 60% to 80% stenosis before the vProtect Luminal Shields were deployed.

In the first patient, a 75% occlusion in the mid-circumflex coronary artery underwent pre-dilatation at low pressure with a 2.5 x 9 mm balloon and then received a 3.5 x 15 mm luminal shield. After gentle post-dilatation, angiography revealed that blood flow had been restored to the distal portion of the treated vessel.

In the second patient, an 80% occlusion in the middle of the left anterior descending (LAD) branch required pre-dilatation with a 2.5 x 9 mm balloon. Additional lumen gain was achieved by Shield placement and post-dilatation, again achieving restoration of blood flow distal to the treated segment.

The third patient was a challenging case with a 65% occlusion in the mid-LAD, located in a bend near a side branch ostium. The vProtect Luminal Shield was chosen for this patient based on its mechanical properties, including high vascular conformability. Because of its flexibility, the vProtect Luminal Shield was able to access the tortuous anatomy and cross the lesion successfully. Restoration of flow was achieved without angiographic evidence of straightening of the target vessel, a common occurrence with rigid balloon-expandable stents. In addition, the side branch was preserved without evidence of plaque shifting or worsening stenosis.

"The vProtect Luminal Shield and delivery system performed extremely well," according to Dr. Granada. "The three patients we treated presented with lesions representative of what we see in daily clinical practice and we were able to cross these lesions and deliver the device safely in each case. Although the vProtect Luminal Shield has ultra-thin struts to promote healing, it maintains an intrinsic radial force that matches the vessel compliance. I am very pleased with these early results," Dr. Granada said.

For more information about Prescient Medical and its products, contact Ilana Odess at (917) 941-9990.

About Prescient Medical, Inc.

Prescient Medical, Inc. is a privately held medical device company dedicated to reducing deaths from heart attacks, the leading cause of death in much of the world. For more information, please visit our website at http://www.prescientmedical.com or call +1-866-376-0500.


'/>"/>
SOURCE Prescient Medical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Prescient Medical, Inc. Acquires New Technology to Detect Inflammation in Coronary Blood Vessels
2. Pharmacopeias First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients
3. CureDMs Diabetes Therapy Achieves Major Development Milestone
4. EntreMed Achieves a Key Milestone Through Initiation of ENMD-2076 Clinical Program
5. Bionomics Achieves US$1 Million Milestone Payment from Genmab
6. Lotus Pharmaceuticals, Inc. Achieves Significant Milestones in the Development of Isosorbide Mononitrate Sustained Release Tablets
7. Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus
8. Surface Logix Achieves Objectives With SLx-2101 in Phase 2a Clinical Trial in Hypertension
9. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
10. PLC Systems Achieves Successful Early Conclusion of RenalGuard(TM) Pilot Safety Trial
11. Cethromycin Achieves All Endpoints in Second Pivotal Phase III Trial for Treatment of Pneumonia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Medical Market Analysis 2016 - Forecast to 2022" report ... The report contains up to date financial data derived from ... of major trends with potential impact on the market during ... market segmentation which comprises of sub markets, regional and country ...
(Date:6/23/2016)... June 23, 2016 Bracket , a leading ... next generation clinical outcomes platform, Bracket eCOA (SM) 6.0, ... June 26 – 30, 2016 in Philadelphia ... Clinical Outcome Assessment product of its kind to fully integrate ... Bracket eCOA 6.0 is a flexible platform for electronic ...
(Date:6/23/2016)... -- Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered in ... . ... ... ... Astellas is ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A ... 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, where the ... history as home to some of the world’s leading providers of cereal and other ...
(Date:6/25/2016)... D.C. (PRWEB) , ... June 25, 2016 , ... ... discuss health policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, ... their work on several important health care topics including advance care planning, healthcare ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern ... Laude and his M.D from the David Geffen School of Medicine at UCLA. He ... Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may ... to unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To ... for healthy coping following a traumatic event. , Trauma sufferers tend to feel a ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. ... accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of orthodontics, ... and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic ...
Breaking Medicine News(10 mins):